stockrow
Saturday 7 November 2026
Export ARDX’s income statement to Excel — free account
Ardelyx, Inc.
ARDX Healthcare Biotechnology
Ardelyx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $407.3 million, up 22.1% from fiscal 2024.
- Revenue
- +15.7%
- EPS
- +27.5%
- Free cash flow
- +938.8%
- Total debt
- +24.8%
Quarter to September 2026, against a year earlier
2.86
0.13
−4.35%
Follow ARDX
Alert me
Ardelyx, Inc. (ARDX) P/E ratio
Ardelyx, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 733× (September 2015) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 33 more quarters | Free account |
Against its own ten years
Low 0.0×
High 733×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| SANA Sana Biotechnology, Inc. compare | n/m |
| ALMS Alumis Inc. compare | n/m |
| LXRX Lexicon Pharmaceuticals, Inc. compare | n/m |
| OABI OmniAb, Inc. compare | n/m |
| PRME Prime Medicine, Inc. compare | n/m |
| ARDX Ardelyx, Inc. | n/m |
| ANNX Annexon, Inc. compare | n/m |
| CGEM Cullinan Therapeutics, Inc. compare | n/m |
| MGTX MeiraGTx Holdings PLC compare | 11.8× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)